IMW 2019 | Translating MRD assessment into routine clinical practice

Sarah Holstein

Sarah Holstein, MD, PhD, University of Nebraska Medical Center, Omaha, NE, maps out the future of measurable residual disease (MRD) assessment in clinical trial practice and the current limitations of the method outside of a clinical trial context at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video